Description BPC-157 (Body Protection Compound-157, CAS 137525-51-0) is a synthetic 15-amino-acid pentadecapeptide derived from a sequence identified in human gastric juice, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
By combining these mechanisms, GLP-1 medications make weight loss more effective and sustainable
When your body loses water and sodium faster than usual, you may experience fatigue, dizziness, or headaches that feel unrelated to digestion
GLP-1 Market Share, By Indication, 2025 (%) The obesity and weight management segment held a 28% share of the market in 2025 and is expected to grow at the fastest CAGR of 18.6% during the projection period
We excluded patients with cirrhotic liver, history of gall bladder, biliary disorders, pancreatic diseases, interrupted use of GLP-1RAs throughout the study period, and patients used other drugs with potential effects on the motility of biliary tracts such as cholecystokinin, motilin hormone, cholinomimetic agents like prostigmine, erythromycin, cisapride, cholystyramine, intravenous aminoacids, cholinergic agents like atropine, somatostatin, and progesterone, trimebutine, loperamide and ondansetron
